A twenty six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naïve patients with uncontrolled type 2 diabetes mellitus, with 6 month extension.

Trial Profile

A twenty six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo compared to standard of care insulin for initiating basal insulin in insulin naïve patients with uncontrolled type 2 diabetes mellitus, with 6 month extension.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REACH CONTROL
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 23 Jan 2016 Status changed from planning to recruiting as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top